Published in Vaccine Weekly, March 29th, 2006
Study 1: Dendritic cells were essential for priming but inefficient for boosting antitumor immune response in an orthotopic murine glioma model.
Investigators in France report, "The prognosis of malignant gliomas remains dismal and alternative therapeutic strategies are required. Immunotherapy with dendritic cells (DCs) pulsed with tumor antigens emerges as a promising approach. Many parameters influence the efficacy of DC-based vaccines and need to be optimized in preclinical models. The present study compares different vaccine schedules using DCs loaded with tumor...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2006-03-29)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.